Pushing the boundaries of innovation
The Advanced Diagnostics Laboratory promotes diagnostic innovation at Mayo Clinic. Our lab is a collaboration between Mayo Clinic’s Department of Laboratory Medicine & Pathology and the Center for Individualized Medicine designed to continue Mayo Clinic’s long tradition of innovation and pioneering diagnostics to improve care for patients.
Our unique collaborative approach and atmosphere allows us to effectively partner on ideas and innovation in new diagnostic technologies both internally and with diagnostic companies outside of Mayo Clinic. We work hand in hand with our partners to identify, invest in, and develop differentiated services and products to help improve patient care both inside and outside of Mayo Clinic.
In an ever-changing world, the Advanced Diagnostics Laboratory can be quickly and strategically modified to meet each project’s unique needs. This flexible approach to collaboration brings together different areas of expertise, different technologies, and different partners to pursue new ideas and help grow them beyond our own walls.
The ability to form strategic partnerships with external companies while also working side by side with our own experts, colleagues, and clinicians from across Mayo Clinic allows us to be nimble and foster new diagnostic innovations.
At a glance…
We're dedicated to our patients' health and well-being,
and proud of the outstanding outcomes we achieve
square feet of collaboration space
COVID-19 innovation projects completed within 1 year
active innovation projects, along with 25 innovation projects completed since inception
specialized collaboration laboratories
Interested in learning more? Connect with us.
In a groundbreaking study, Mayo Clinic investigators have developed a multiomic molecular method to predict clinical COVID-19 (SARS-CoV-2) outcomes better than traditional cytokines. Using a machine-learning-based prediction model, the team identified 102 biomarkers, which include several novel cytokines and other proteins, lipids, and metabolites. The discovery may help clinicians reliably predict a more severe course of COVID-19 before the patient gets sick enough to be hospitalized. Until now, there have been no biomarkers that can reliably predict which patients are more likely to have severe illness.
In Mayo Clinic’s Advanced Diagnostics Laboratory, there are dozens of projects underway at once to develop new technologies, discover novel findings, validate new tests, and support physicians in providing advanced patient care. For example, researchers are using phage immunoprecipitation sequencing (PhIP-Seq) to discover new serological biomarkers for autoimmune diseases. In a recent study using PhIP-Seq, Mayo Clinic researchers discovered a previously unknown antibody marker for immune-mediated rippling muscle disease (iRMD). This finding will support testing options and accurate diagnosis of iRMD, helping physicians treat patients with iRMD and restore their quality of life.
In a recent study, Mayo Clinic researchers developed the first cellular DNA barcoding with a machine-learning approach to reveal previously unknown metastatic behavior of tumor cells. Researchers barcoded the DNA of millions of human ovarian cancer cells and transplanted them in mice, where rare tumor initiating cells and their progenies could be tracked within the primary tumor as well as in every other organ they were spreading into. The entire community of cells generated by a single barcoded cell had identical barcodes. This enabled the tracking of a large number of benign and metastatic clones by sequencing DNA barcodes in tumors and various organs, including blood and ascites. Using the cellular DNA barcoding approach and a newly developed data analysis system, researchers could track clonal growth dynamics in various metastatic sites and trace it back to its ancestral tumor-initiating cell. They used artificial intelligence to tackle the complex data to identify if the clonal metastatic spread is happening peritoneally or through blood routes.